develop
effect
immunotherapi
lung
cancer
daunt
huge
attract
challeng
recent
nonsmal
cell
lung
cancer
thought
nonimmunogen
tumor
evid
highlight
integr
role
play
inflammatori
immunolog
respons
lung
carcinogenesi
despit
recent
encourag
preclin
phase
iii
data
pauciti
phase
iii
trial
show
clear
clinic
benefit
vaccin
lung
cancer
mani
difficulti
overcom
prior
develop
success
therapi
perhap
measur
immun
respons
may
translat
clinic
meaning
radiolog
respons
patient
select
may
also
problem
ongo
clinic
studi
major
trial
lung
cancer
vaccin
focus
patient
advancedstag
diseas
ideal
candid
may
patient
lower
tumor
burden
stage
ii
diseas
select
exact
antigen
target
also
difficult
like
requir
multipl
epitop
divers
set
gene
restrict
multipl
haplotyp
gener
truli
effect
vaccin
abl
overcom
variou
immunolog
escap
mechan
tumor
employ
review
discuss
activ
immunotherapi
employ
proteinpeptid
vaccin
whole
cell
vaccin
dendrit
cell
vaccin
examin
current
data
novel
immunomodul
agent
lung
cancer
account
approxim
one
third
cancerrel
death
unit
state
surgic
resect
truli
cur
therapi
relaps
rate
greater
definit
resect
improv
therapeut
adjuv
set
requir
advanc
stage
diseas
system
chemotherapi
andor
local
irradi
produc
object
respons
palliat
symptom
howev
therapi
offer
modest
improv
surviv
twoyear
surviv
rate
stage
iiib
iv
nonsmal
cell
lung
cancer
nsclc
respect
surviv
rate
respect
despit
avail
platinumbas
chemotherapi
doublet
agent
docetaxel
pemetrex
erlotinib
refractori
diseas
overal
outcom
still
poor
immunotherapi
provid
uniqu
approach
potenti
consolid
surgeri
andor
standard
chemotherapi
stimul
immun
system
induc
cellular
immun
respons
har
cytotox
lymphocyt
ctl
capabl
select
destroy
cancer
cell
target
tumorassoci
antigen
taa
could
result
tumor
erad
use
lymphocyt
therapeut
intervent
take
advantag
immun
system
specif
surveil
properti
memori
induct
abil
immun
system
circul
throughout
bodi
could
theori
allow
remov
micrometastas
remain
silent
grow
clinic
signific
furthermor
immun
system
abil
gener
longlast
memori
endur
immun
respons
may
protect
new
tumor
develop
cellular
immun
initi
uptak
antigen
antigenpres
cell
apc
dendrit
cell
dc
intern
short
peptid
sequenc
antigen
present
extracellular
surfac
apc
conjunct
major
histocompat
complex
mhc
molecul
dc
move
peripheri
drain
lymph
node
come
contact
lymphocyt
complex
reaction
involv
specif
tcell
receptor
apc
mhcpeptid
molecul
well
activ
costimulatori
molecul
requir
activ
ctl
fig
activ
ctl
circul
recogn
cell
display
complementari
peptidemhc
class
molecul
cell
surfac
cell
death
occur
via
combin
either
granul
exocytosi
express
fa
ligand
lead
apoptosi
fig
memori
lymphocyt
produc
allow
rapid
tcell
respons
event
futur
challeng
antigen
cytokin
play
import
role
regul
immun
system
either
direct
respons
toward
activ
downregul
cancer
patient
develop
degre
tumor
toler
may
result
lack
proper
costimulatori
molecul
upon
initi
antigen
present
tumor
cell
also
evad
immun
system
downregul
immun
cytokin
develop
resist
ctl
lung
cancer
cell
shown
produc
varieti
immunosuppress
molecul
includ
prostaglandin
affect
dc
process
present
well
acquisit
express
ctl
effector
cell
function
current
vaccin
approach
focu
coupl
immunogen
adjuv
agent
tumor
antigen
adjuv
agent
typic
mix
tumor
cell
tumor
antigen
admixtur
use
vaccin
patient
adjuv
agent
strongli
immunogen
apc
respond
vaccin
digest
adjuv
agent
along
admix
tumor
antigen
present
adjuv
agent
tumor
antigen
cell
attempt
made
strengthen
immun
respons
incorpor
natur
secret
immun
modul
vaccin
strategi
includ
genet
modifi
autolog
tumor
cell
allogen
cell
line
secret
cytokin
andor
costimulatori
molecul
anoth
way
boost
immun
system
express
antigen
viral
vector
also
design
encod
costimulatori
molecul
cytokin
discoveri
tolllik
receptor
increas
interest
use
dnabas
vaccin
cancer
dna
plasmid
vaccin
contain
unmethyl
cpg
site
stimul
tolllik
receptor
apc
approach
includ
prime
immun
system
use
vaccin
contain
autolog
dc
load
tumor
antigen
elicit
tumorspecif
ctl
respons
immunotherapeut
approach
lung
cancer
includ
activ
immunotherapi
vaccin
passiv
immunotherapi
monoclon
antibodi
adopt
cell
transfer
cytokin
therapi
nonspecif
immunotherapi
focu
review
protein
antigenbas
vaccin
peptid
antigenbas
vaccin
whole
tumor
cell
vaccin
dc
vaccin
promis
nonspecif
immunomodulatori
treatment
melanomaassoci
antigen
mage
taa
express
cancer
cell
mage
express
normal
tissu
except
male
germ
cell
line
devoid
mhc
molecul
therefor
unabl
present
magea
antigen
silent
gene
germ
line
cell
within
magea
famili
consid
promis
immunotherapi
target
express
nsclc
rate
express
increas
diseas
spread
stage
patient
stage
ii
patient
express
primari
tumor
express
thu
associ
poor
prognosi
random
phase
ii
trial
patient
complet
resect
stage
ib
ii
nsclc
compar
postop
inject
recombin
protein
combin
adjuv
system
x
follow
x
vs
placebo
report
tabl
median
followup
month
diseasefre
surviv
overal
surviv
hazard
ratio
hr
ci
ci
respect
favor
group
none
outcom
endpoint
reach
statist
signific
howev
signal
respect
surviv
benefit
consid
strong
enough
warrant
phase
iii
evalu
recent
paper
report
analysi
gene
express
profil
tumor
prior
treatment
identifi
predict
signatur
correl
clinic
activ
antigenspecif
immunotherapi
overal
popul
resect
stage
ibii
nsclc
treatment
decreas
rel
risk
recurr
hr
ci
popul
predict
gene
signatur
treatment
decreas
rel
risk
recurr
hr
ci
magrit
adjuv
nonsmal
cell
lung
cancer
immunotherapi
studi
current
recruit
countri
patient
resect
stage
ib
iiia
nsclc
expect
enrol
follow
adjuv
chemotherapi
patient
randomli
assign
receiv
inject
vaccin
placebo
period
diseasefre
surviv
primari
endpoint
trial
registri
defin
type
adjuv
chemotherapi
epiderm
growth
factor
cell
membran
receptor
egfr
known
overexpress
mani
epitheli
tumor
includ
lung
cancer
last
decad
sever
small
molecul
inhibitor
egfrassoci
tyrosin
kinas
monoclon
antibodi
target
egfr
develop
vaccin
consist
human
recombin
egf
conjug
carrier
protein
deriv
neisseria
meningitid
evalu
pilot
clinic
trial
pool
analysi
accru
total
patient
stage
iiib
iv
nsclc
perform
tabl
alum
use
vaccin
adjuv
one
studi
singl
dose
cyclophosphamid
mgm
administ
day
prior
treatment
egf
vaccin
vaccin
patient
least
doubl
baselin
antiegf
antibodi
titer
seroconvers
increas
baselin
level
patient
titer
consid
good
antibodi
respond
gar
surviv
better
patient
seroconvert
mean
month
median
month
compar
patient
mean
month
median
month
addit
surviv
advantag
gar
mean
month
median
month
compar
poor
antibodi
respond
mean
month
median
month
signific
toxic
note
nening
vinagera
et
al
conduct
random
phase
ii
control
trial
egf
vaccin
patient
stage
iiibiv
nsclc
complet
firstlin
chemotherapi
eighti
patient
randomli
assign
receiv
best
support
care
egf
vaccin
compar
vaccin
patient
control
median
overal
surviv
show
trend
toward
surviv
advantag
month
vs
month
p
subset
vaccin
patient
year
age
surviv
significantli
longer
month
vs
month
p
vaccin
safe
well
toler
direct
correl
gar
surviv
decreas
serum
egf
surviv
paramet
propos
marker
optim
vaccin
dosag
schedul
futur
clinic
trial
clinic
trial
reevalu
approach
larger
patient
seri
ongo
mucin
mucin
transmembran
glycoprotein
overexpress
underor
aberrantli
glycosyl
mani
human
malign
normal
restrict
apic
surfac
polar
epitheli
cell
includ
respiratori
tract
mani
epitheli
malign
overexpress
lose
polar
express
larg
nh
termin
ectodomain
becom
underor
aberrantli
glycosyl
shorten
carbohydr
side
chain
unmask
epitop
peptid
core
act
tumorassoci
neoepitop
precis
role
promot
tumor
cell
growth
surviv
unclear
thought
involv
tumorigen
tumor
cell
migrat
increas
resist
stressinduc
apoptosi
chemotherapeut
agent
high
serum
level
associ
immun
suppress
poor
prognosi
patient
advanc
adenocarcinoma
thought
cell
overexpress
tumorassoci
may
escap
strong
host
immun
respons
make
attract
target
cancer
immunotherapi
liposom
vaccin
target
expos
core
peptid
taa
lyophil
prepar
consist
lipopeptid
immunoadjuv
monophosphoryl
lipid
lipid
cholesterol
dimyristoyl
phosphatidylglycerol
dipalmitoyl
phosphatidylcholin
form
liposom
product
vaccin
design
induc
cellular
immun
respons
may
lead
immun
reject
tumor
tissu
express
antigen
random
phase
iib
trial
patient
stage
iiibiv
nsclc
stabl
diseas
respons
primari
chemotherapi
complet
tabl
fig
given
weekli
week
administ
differ
site
improv
vaccin
uptak
drain
lymph
node
option
proceed
mainten
therapi
consist
vaccin
everi
week
start
week
patient
receiv
singl
infus
cyclophosphamid
mgm
day
vaccin
administr
shown
reduc
activ
suppressor
cell
studi
power
detect
differ
surviv
hr
power
onesid
p
patient
vaccin
arm
best
support
care
bsc
arm
treatment
toler
patient
vaccin
arm
complet
plan
inject
proceed
mainten
phase
common
advers
event
grade
flulik
symptom
event
relat
cyclophosphamid
administr
mild
injectionsit
reaction
tcell
prolifer
assay
perform
baselin
immun
sampl
evalu
demonstr
antigenspecif
tcell
respons
median
overal
surviv
month
vaccin
arm
vs
month
bsc
differ
reach
statist
signific
p
unadjust
cox
surviv
rate
arm
vs
bsc
arm
greatest
differ
surviv
observ
patient
stage
iiib
locoregion
diseas
adjust
hr
ci
p
recent
report
studi
median
followup
month
updat
observ
surviv
rate
patient
stage
iiib
locoregion
diseas
median
surviv
month
arm
vs
bsc
arm
median
surviv
month
multicent
phase
iii
random
doubleblind
placebocontrol
studi
cancer
vaccin
liposom
vaccin
nsclc
subject
unresect
stage
iii
diseas
current
recruit
start
stimul
target
antigen
respons
nsclc
trial
expect
recruit
patient
respons
stabl
diseas
least
cycl
definit
platinumbas
chemoradi
tumor
express
wide
varieti
taa
potenti
taa
loss
addit
patient
differ
tcell
repertoir
suggest
success
vaccin
may
need
incorpor
wide
select
ctl
specif
vaccin
design
overcom
potenti
difficulti
induc
ctl
respons
taa
frequent
overexpress
nsclc
carcinoembryon
antigen
cea
compos
synthet
peptid
taa
repres
ctl
epitop
tenth
pandr
epitop
design
augment
ctl
respons
phase
ii
studi
investig
efficaci
patient
metastat
nsclc
tabl
oneyear
surviv
treat
group
median
surviv
month
one
patient
complet
respons
one
partial
respons
phase
iii
valid
trial
patient
advanc
nsclc
anticip
develop
cancer
therapi
potenti
major
signific
use
nonantigenspecif
vaccin
target
immunomodulatori
molecul
therapeut
reeduc
cell
induc
antitumor
immun
respons
tumor
cell
vaccin
divid
broad
categori
autolog
tumor
cell
line
without
gene
modif
cell
suspens
resect
tumor
transfect
granulocytemacrophag
colonystimul
factor
gmcsf
allogen
tumor
cell
line
vaccin
compos
whole
tumor
cell
genet
modifi
secretegmcsf
initi
vaccin
use
autolog
irradi
tumor
cell
transfect
nonrepl
adenovir
vector
engin
secret
gmcsf
phase
trial
involv
patient
stage
iv
nsclc
vaccin
well
toler
toxic
restrict
grade
local
skin
reaction
vaccin
demonstr
activ
patient
stabl
diseas
patient
demonstr
diseas
surgic
resect
known
metastat
site
prior
vaccin
achiev
prolong
remiss
month
base
promis
result
larger
phase
iii
trial
report
tabl
trial
consist
cohort
patient
stage
ib
ii
nsclc
patient
stage
iii
iv
diseas
patient
underw
tumor
harvest
treat
advanc
diseas
three
advancedstag
patient
bronchioloalveolar
carcinoma
durabl
complet
respons
last
month
interestingli
secret
gmcsf
vaccin
shown
correl
outcom
longer
surviv
observ
patient
receiv
vaccin
secret
gmcsf
cell
median
surviv
month
ci
month
patient
receiv
vaccin
secret
less
gmcsf
median
surviv
month
ci
month
p
result
studi
suggest
vaccin
doserel
surviv
advantag
subsequ
trial
evalu
unmodifi
tumor
cell
combin
allogen
bystand
cell
line
human
erythroleukemia
cell
line
genet
modifi
secret
higher
level
gmcsf
combin
refer
bystand
vaccin
requir
genet
modif
individu
autolog
tumor
cell
prepar
provid
substanti
higher
consist
gmcsf
secret
fortynin
patient
stage
iiia
iv
nsclc
receiv
vaccin
unlik
previou
studi
none
achiev
partial
complet
tumor
respons
tabl
specul
deriv
bystand
cell
line
may
detract
gmcsf
abil
boost
immun
respons
taa
induct
myeloid
suppressor
cell
associ
impair
antigenspecif
tcell
respons
conclud
gmcsf
secret
tumor
cell
recombin
purifi
protein
recent
data
phase
iii
clinic
trial
util
approach
cancer
set
demonstr
improv
surviv
compar
standard
chemotherapi
lead
uncertainti
futur
platform
transform
growth
factorbeta
part
famili
multifunct
protein
isoform
regul
growth
function
mani
normal
neoplast
cell
process
term
paradox
either
oncogen
tumor
suppressor
effect
stimul
inhibit
cell
growth
mani
tumor
includ
lung
cancer
produc
high
level
latent
activ
elev
level
correl
tumorassoci
immunosuppress
suppress
natur
killer
nk
cell
dc
activ
identifi
poor
prognost
factor
nsclc
number
celland
dcassoci
mechan
propos
explain
activ
includ
impair
high
affin
receptor
function
express
lead
inhibit
ctl
activ
also
abl
convert
cell
regulatori
cell
induc
transcript
factor
regulatori
cell
specif
prevent
immun
activ
dc
play
crucial
role
induct
antitumor
immun
tumorbear
host
process
antigen
crosspresent
immatur
dc
unabl
stimul
potent
immun
respons
block
matur
dc
inhibit
abil
present
antigen
vaccin
belagenpumatucel
lucanix
mixtur
allogen
nsclc
cell
line
genet
modifi
secret
antisens
oligonucleotid
rational
use
cell
cocktail
vaccin
base
observ
nsclc
tumor
cell
line
share
immunogen
epitop
primari
tumor
mhc
class
irestrict
ctl
gener
specif
human
lung
adenocarcinoma
cell
line
exhibit
demonstr
cytotox
lung
cancer
cell
line
increas
array
tumor
antigen
present
vaccin
belagenpumatucel
employ
cell
line
express
low
level
due
prior
transfect
antisens
plasmid
anticip
downregul
express
vaccin
mitig
major
sourc
immun
suppress
vaccin
inject
site
hypothesi
inject
allogen
tumor
cell
downregul
enhanc
local
immun
recognit
activ
effector
cell
lead
system
immun
respons
capabl
target
patient
nativ
tumor
random
phase
ii
trial
patient
stage
ii
iv
nsclc
random
intraderm
inject
dose
level
cellsinject
cell
inject
cellsinject
monthli
everi
month
schedul
maximum
inject
tabl
fig
signific
advers
event
report
doserel
surviv
differ
demonstr
patient
receiv
cellsinject
p
analysi
suggest
cohort
receiv
dose
cellsinject
signific
surviv
advantag
compar
cohort
p
patient
latestag
nsclc
iiibiv
partial
respons
estim
probabl
surviv
year
respect
higherdos
group
combin
respect
lowdos
group
estim
median
surviv
patient
receiv
cellsinject
day
compar
day
patient
receiv
cellsinject
p
differ
overal
surviv
dose
cohort
stage
iiiiv
patient
statist
signific
p
increas
cytokin
product
p
p
p
observ
among
clinic
respond
partial
respons
stabl
diseas
also
display
elev
antibodymedi
respons
vaccin
p
phase
iii
investig
use
dose
cellsinject
ongo
mainten
therapi
patient
unresect
stage
iiiiv
nsclc
respond
stabl
diseas
firstlin
platinumbas
chemotherapi
investig
suggest
target
tumor
antigen
alon
may
elicit
strong
enough
immun
respons
therapeut
benefit
discoveri
dc
profession
apc
herald
use
develop
cancer
vaccin
propos
manipul
dc
vaccin
adjuv
may
effect
way
stimul
antitumor
immun
overcom
toler
princip
purpos
dcbase
immunotherapi
induc
antigenspecif
immun
respons
stimul
matur
factor
inflammatori
cytokin
via
dc
upregul
adhes
costimulatori
molecul
becom
termin
differenti
stimul
tcell
immun
effector
arm
antitumor
respons
cell
becom
activ
antigen
present
apc
upon
administr
dcbase
vaccin
dc
migrat
secondari
lymphoid
organ
induc
antigenspecif
immun
respons
small
phase
iii
trial
dc
vaccin
patient
nsclc
report
common
antigen
use
cea
glycoprotein
act
adhes
molecul
overexpress
nsclc
human
leukocyt
antigen
hla
restrict
class
cea
peptid
alter
peptid
use
antigen
studi
cea
peptid
must
modifi
effect
immunogen
hirschowitz
et
al
report
studi
patient
nsclc
rang
stage
ia
iiib
receiv
dcbase
vaccin
object
studi
evalu
toler
measur
immunolog
respons
heterogen
group
nsclc
patient
autolog
dc
gener
ex
vivo
monocyt
precursor
load
apoptot
bodi
allogen
adenocarcinoma
cell
line
overexpress
taa
cea
wilm
tumor
survivin
two
dose
vaccin
consist
cell
administ
intraderm
one
month
apart
immun
reactiv
measur
vitro
show
distinct
pattern
patient
show
measur
immun
reactiv
show
reactiv
autolog
dc
absenc
tumor
antigen
tumorindepend
respons
show
tumorspecif
immun
respons
immunolog
respons
independ
stage
prior
therapi
correl
immun
respons
clinic
outcom
continu
studi
addit
patient
given
vaccin
studi
evalu
immunolog
respons
immatur
antigenpuls
autolog
dc
vaccin
distinct
group
nsclc
patient
seven
patient
undergon
surgic
resect
stage
iii
without
adjuv
therapi
unresect
stage
iii
diseas
treat
chemoradi
alon
four
stage
iii
unresect
stage
iii
surgic
resect
patient
includ
resect
patient
also
receiv
adjuv
chemoradi
demonstr
immun
respons
vaccin
clear
indic
therapeut
efficaci
note
anoth
studi
patient
nsclc
vaccin
dc
load
peptid
tumor
lysat
surviv
advantag
observ
vaccin
patient
whose
tumor
found
express
compar
patient
tumor
month
vs
month
p
seven
patient
tumor
clinic
respons
includ
one
complet
respons
patient
exhibit
partial
respons
vaccin
peptid
rather
tumor
lysat
achiev
greater
immun
respons
better
antigen
present
research
use
differ
mechan
deliv
vaccin
apc
mors
et
al
ad
antigen
directli
ex
vivogener
dc
via
engin
fowlpox
viru
express
fulllength
cea
tricom
adjuv
agent
consist
costimulatori
molecul
intracellular
adhes
molecul
icam
lymphocyt
functionassoci
antigen
lfa
patient
enrol
nsclc
tcell
respons
induc
patient
stabl
diseas
month
author
report
respond
underli
diseas
anoth
studi
use
modifi
vaccinia
viru
engin
express
entir
gene
vaccin
patient
advanc
cancer
express
three
patient
enrol
nsclc
stabl
diseas
month
induc
tcell
respons
talactoferrin
alfa
also
known
recombin
human
lactoferrin
recombin
version
glycoprotein
express
purifi
aspergillu
niger
var
awamor
talactoferrin
structur
function
similar
nativ
human
lactoferrin
purifi
human
milk
known
differ
natur
glycosyl
lactoferrin
member
transferrin
famili
nonhem
ironbind
protein
found
mammalian
serum
exocrin
secret
milk
semin
fluid
intestin
secret
tear
sweat
saliva
nasal
secret
secretori
granul
neutrophil
lactoferrin
demonstr
antiinflammatori
antiinfect
antitumor
properti
lactoferrin
wide
array
immunomodulatori
function
includ
activ
nk
lymphokineactiv
killer
cell
enhanc
pmn
macrophag
cytotox
lactoferrin
demonstr
anticanc
activ
broad
rang
tumor
type
talactoferrin
oral
activ
immunomodulatori
protein
specif
bind
receptor
cell
line
upper
gastrointestin
tract
initi
immunostimulatori
cascad
gutassoci
lymphoid
tissu
galt
talactoferrin
thought
act
chemokin
bind
chemokin
receptor
induc
chemotaxi
immun
cell
includ
effector
cell
lymphocyt
apc
administ
talactoferrin
transport
cell
peyer
patch
small
intestin
dc
bear
tumor
antigen
galt
recruit
matur
talactoferrin
also
induc
product
key
cytokin
galt
includ
cytokin
play
import
role
stimul
innat
adapt
immun
promot
matur
prolifer
immun
cell
anticanc
nk
cell
lymphocyt
nkt
cell
preclin
experi
oral
administr
talactoferrin
produc
increas
total
cellular
small
intestin
peyer
patch
includ
increas
number
nkt
cell
lymphocyt
hope
administr
talactoferrin
activ
tumordrain
lymph
node
lead
cellular
infiltr
tumor
ultim
tumorcel
death
phase
studi
refractori
solid
tumor
oral
talactoferrin
alfa
well
toler
show
promis
diseas
activ
three
patient
studi
nsclc
show
signific
slow
rate
growth
develop
new
metastat
lesion
patient
remain
studi
month
aggreg
averag
rate
tumor
growth
drop
month
month
rel
decreas
hope
sustain
decreas
rate
tumor
growth
could
translat
improv
progressionfre
overal
surviv
phase
ii
iii
studi
talactoferrin
alfa
two
companysponsor
trial
conduct
patient
nsclc
first
random
phase
ii
studi
patient
local
advanc
metastat
stage
iiibiv
nsclc
fail
firstor
secondlin
chemotherapi
studi
enrol
patient
receiv
one
vial
bid
either
g
talactoferrin
n
placebo
n
cycl
cycl
consist
consecut
week
studi
drug
follow
week
patient
talactoferrin
arm
increas
median
overal
surviv
compar
placebo
arm
month
vs
month
p
hr
also
show
trend
toward
improv
progressionfre
surviv
talactoferrin
well
toler
second
phase
ii
studi
use
talactoferrin
placebo
combin
carboplatin
paclitaxel
patient
local
advanc
andor
metastat
nsclc
stage
iiibiv
respons
rate
increas
placebo
arm
talactoferrin
arm
absolut
improv
rel
improv
p
median
overal
surviv
increas
intenttotreat
popul
month
talactoferrin
vs
month
placebo
safeti
data
indic
talactoferrin
chemotherapi
well
toler
patient
popul
fortism
ongo
phase
iii
random
doubleblind
placebocontrol
studi
oral
talactoferrin
plu
bsc
patient
nsclc
fail
prior
treatment
regimen
oligonucleotid
contain
certain
cpg
sequenc
motif
stimul
innat
adapt
immun
respons
tlr
famili
highli
conserv
receptor
regul
innat
antigenspecif
immun
recogn
pathogenassoci
molecular
pattern
express
b
lymphocyt
plasmacytoid
cell
dc
activ
may
reduc
immun
toler
improv
tumor
antigen
recognit
cell
death
via
innat
specif
immun
system
signal
pathway
immunostimulatori
oligonucleotid
activ
complex
cascad
lead
stimul
immun
respons
increas
product
proinflammatori
cytokin
chemokin
agonist
enhanc
matur
plasmacytoid
dendrit
cell
pdc
matur
pdc
exhibit
increas
cellsurfac
express
mhc
class
ii
molecul
costimulatori
molecul
secret
cytokin
associ
h
respons
secondarili
activ
nk
cell
monocyt
neutrophil
induct
rapid
innat
immun
respons
follow
adapt
antigenspecif
immun
respons
present
tumor
antigen
ctl
agonist
reduc
threshold
antigen
stimul
b
cell
enhanc
differenti
antibodysecret
plasma
cell
potenti
promot
antibodydepend
cellular
cytotox
shown
express
mani
lung
cancer
cell
line
lung
cancer
specimen
wherea
nonmalign
lung
tissu
express
low
level
thought
stimul
immun
system
lead
antitumor
effect
cpg
oligonucleotid
formerli
known
cpg
synthet
nucleaseresist
oligodeoxynucleotid
mimic
natur
ligand
unmethyl
cpg
motif
therebi
induc
cascad
immun
reaction
potenti
promot
antitumor
immun
respons
multicent
random
phase
ii
trial
chemotherapyna
patient
stage
iiibiv
nsclc
patient
random
receiv
cycl
standard
regimen
carboplatin
paclitaxel
alon
mgkg
sc
day
cycl
median
surviv
month
arm
vs
month
chemotherapyalon
arm
surviv
respect
hr
overal
surviv
ci
p
basi
phase
ii
trial
random
intern
multicent
phase
iii
trial
commenc
compar
plu
platinumbas
chemotherapi
paclitaxel
plu
carboplatin
gemcitabin
plu
cisplatin
chemotherapi
alon
patient
local
advanc
metastat
nsclc
trial
discontinu
interim
analysi
independ
data
monitor
safeti
committe
conclud
provid
addit
benefit
term
overal
surviv
progressionfre
surviv
standard
platinumbas
doublet
chemotherapi
attract
focu
immunotherapi
use
antiidiotyp
monoclon
antibodi
mab
neuglycosyl
neugc
contain
gangliosid
carbohydr
determin
known
undergo
extens
chang
cours
malign
transform
g
monosialogangliosid
contain
one
nacetyl
sialic
acid
residu
mani
human
cancer
express
nonhuman
sialic
acid
nglycolyl
sialic
acid
neugc
known
immunogen
human
design
hanganutziudeich
hd
antigen
glycolipid
differenti
pattern
express
normal
human
tissu
malign
cell
make
potenti
relev
therapeut
target
vaccin
prepar
contain
murin
antiidiotyp
mab
react
neugccontain
gangliosid
antigen
phase
clinic
trial
shown
favor
toxic
profil
variou
cancer
type
includ
small
cell
lung
cancer
use
aluminum
hydroxideprecipit
mab
evalu
patient
stage
iiibiv
nsclc
compassionateus
studi
patient
adenocarcinoma
squamou
cell
carcinoma
larg
cell
carcinoma
complet
standard
chemotherapi
radiotherapi
stage
diseas
patient
receiv
biweekli
inject
mg
alum
maintain
good
perform
statu
receiv
dose
interv
overal
surviv
time
initi
vaccin
month
ci
oneyear
surviv
rate
median
surviv
patient
enter
studi
either
partial
respons
stabl
diseas
perform
statu
firstlin
chemoradiotherapi
month
ci
month
oneyear
surviv
rate
patient
commenc
treatment
progress
diseas
perform
statu
median
overal
surviv
month
ci
month
oneyear
surviv
rate
p
ongo
trial
investig
clinic
effect
mab
vaccin
nsclc
patient
partial
respons
stabl
diseas
perform
statu
evalu
correl
immun
respons
induc
antiidiotyp
vaccin
patient
surviv
cytotox
lymphocyteassoci
antigen
critic
element
homeostat
mechan
immunosuppress
tcell
regul
transmembran
protein
express
surfac
activ
lymphocyt
monocyt
weak
antigen
taa
caus
antigenspecif
tcell
respons
via
interact
tcell
receptor
interact
reli
nonantigenspecif
signal
gener
cell
bind
apc
occur
becom
express
tcell
surfac
higher
bind
affin
lead
diminish
immun
respons
decreas
receptor
express
two
potenti
immunolog
strategi
target
molecul
activ
cell
includ
administ
antibodi
agonist
effect
costimulatori
molecul
rapidli
induc
cell
activ
enhanc
tcell
activationprolifer
crosslink
administ
antibodi
antagonist
effect
coinhibitori
molecul
preliminari
phase
data
melanoma
confirm
safeti
antibodi
ongo
phase
ii
studi
multipl
tumor
type
includ
nsclc
phase
ii
studi
evalu
safeti
efficaci
ipilimumab
plu
paclitaxel
carboplatin
vs
paclitaxelcarboplatin
alon
previous
untreat
patient
nsclc
sclc
current
recruit
develop
effect
immunotherapi
lung
cancer
daunt
challeng
recent
nsclc
consid
nonimmunogen
poorli
immunogen
although
unlik
immun
system
abl
adequ
consist
deal
bulki
diseas
effect
immunotherapi
would
ideal
adjuv
follow
initi
clinic
respons
definit
surgic
multimod
medic
therapi
present
limit
data
phase
iii
trial
show
clear
clinic
benefit
vaccin
lung
cancer
one
explan
may
measur
immun
respons
translat
clinic
meaning
respons
patient
select
may
also
problem
ongo
clinic
studi
major
trial
focus
patient
advancedstag
diseas
ideal
candid
lung
cancer
vaccin
may
patient
stage
ii
diseas
consid
high
risk
recurr
postresect
select
optim
tumor
antigen
target
also
problemat
truli
effect
therapeut
lung
cancer
vaccin
may
requir
multipl
epitop
divers
set
gene
restrict
multipl
haplotyp
order
combat
variou
tumor
escap
mechan
hope
ongo
studi
provid
addit
inform
optim
patient
select
vaccin
administr
need
bridg
gap
promis
concept
therapeut
realiti
therebi
expand
thorac
oncologist
armamentarium
fight
lung
cancer
antigen
present
cell
dendrit
cell
process
antigen
peptid
whole
tumor
cell
becom
infect
viral
vector
express
tumor
associ
antigen
present
ex
vivo
puls
peptid
inject
antigen
present
cell
present
tcell
caus
activ
tcell
upon
activ
upregul
inhibit
activ
tcell
antibodi
block
inhibitori
signal
caus
prolong
activ
figur
courtesi
nih
medic
art
